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logic response. However, H-Y serologic response is strongly asso-
ciated with cGVHD in a multivariable logistic model (p  0.007).
These results support the hypothesis that B cell responses to H-Y
mHA play an important role in the pathogenesis of cGVHD and
suggests that anti-B cell therapy may be useful in the treatment of
this disease.
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CHARACTERIZATION OF THE TUMOR-SPECIFIC ACTIVITY OF WT1 SPE-
CIFIC T CELLS GENERATED IN VITRO FROM NORMAL INDIVIDUALS BY
SENSITIZATION WITH WT1-PEPTIDE LOADED AUTOLOGOUS EBV
TRANSFORMED B CELLS
Doubrovina, E.S., Doubrovin, M.M., Shieh, J.H., Bierwiaczonek, A.,
Heller, G., Pamer, E., O’Reilly, R.J. Memorial Sloan-Kettering Cancer
Center, New York, NY
The Wilms’ tumor protein WT1 is over-expressed in most acute
and chronic leukemias. Isolated T-cell clones have been reported
to recognize WT1 peptides binding by HLA-A0201 and HLA-
A2402 and lyse WT1 leukemic lines. To test WT1 peptide
immunogenicity in normal individuals, we sensitized T-cells from
9 HLA-A0201 and 4 HLA-A2402 donors with autologous EBV
transformed B cells (EBV-BLCL) or cytokine-activated monocytes
(CAM), loaded with HLA-A0201-binding WT1 peptides RMFP-
NAPYL or SLGEQQYSV or the HLA- A2402- binding WT1
peptide RVPGVAPTL. WT1-peptide speciﬁc cytotoxic and inter-
feron-gamma producing T-cells were generated from each donor.
T-cells sensitized with peptide-loaded EBV-BLCL generated
higher numbers of WT1 speciﬁc T-cells than peptide loaded
CAM. The frequencies of WT1 peptide-speciﬁc T-cells measured
by binding to peptide-HLA tetramers were similar to those gen-
erated against individual immunogenic HLA-A0201 binding EBV
peptides. These T-cells speciﬁcally lysed WT1 leukemias (n 
16) and solid tumors (n  12) in an HLA-restricted manner, but
neither lysed autologous or HLA-sharing normal CD34 hema-
topoietic progenitor cells (n  12) nor affected their yield of
CFU-GM, BFU-C or CFU-MIX. Following adoptive transfer into
SCID mice bearing subcutaneous xenografts of WT1 and WT1-,
HLA-A0201 leukemias, WT1-peptide-speciﬁc T-cells preferen-
tially accumulated in and induce regressions only of WT1 leu-
kemias . The long-term repeated in vivo scintigraphic imaging of
such T cells, transduced to express an HSV-TK/GFP fusion gene,
following intravenous infusions of the HSV-TK substrate [131I]-
FIAU demonstrated progressive accumulation of the T cells over a
period of 8 days in tumors, expressing targeted antigen and the
HLA restricting allele. These studies demonstrate that T cells
speciﬁc to the self antigen WT1 can be regularly generated from
normal individuals and that these cells exhibit signiﬁcant anti-
tumor activity both in vitro and in vivo. Such cells may prove useful
for adoptive therapy of leukemias in man.
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EX VIVO ACTIVATED AND EXPANDED CD8 T CELLS RECOGNIZE
MALIGNANT CELLS THROUGH A TCR INDEPENDENT AND NKG2D DE-
PENDENT PATHWAY
Verneris, M.R.1, Karami, M.2, Baker, J.2, Jasawal, A.1, Negrin, R.S.2
1. University of Minnesota, Minneapolis, MN; 2. Stanford University,
Stanford, CA
T cells that are activated by TCR crosslinking antibodies and
expanded with high doses of IL-2 attain cytotoxicity against ma-
lignant target cells without prior exposure or antigen priming. The
mechanism of this MHC-unrestricted cytotoxicity is unknown.
NKG2D is a cell surface receptor on both NK and CD8 T cells.
Here we examined ex vivo activated and expanded CD8 T cells to
determine if NKG2D plays a role in the recognition and triggering
of cytotoxicity against malignant targets. FACS analysis showed
that NKG2D could be detected on freshly isolated CD8 cells and
expression is increased after 21 days of culture. To access the
functional role of NKG2D on ex vivo activated and expanded
CD8 T cells we performed 51Cr release assays using NKG2D
blocking antibodies. Blocking NKG2D attenuated the killing of
malignant cell targets by 75%, while control antibodies had no
effect. Similarly, blocking NKG2D counter-ligands on malignant
targets attenuated cytotoxicity by 50-100%. To conﬁrm and ex-
tend these ﬁndings, we designed siRNA against NKG2D. 72 hours
after siRNA transfection, surface NKG2D was nearly undetect-
able, while other proteins (TCR or CD3) were unchanged. Cells
treated with NKG2D siRNA were not cytotoxic, while those
treated with control siRNA had cytotoxicity similar to non-trans-
fected cells. To determine whether NKG2D ligation alone trig-
gered cytotoxicity, we performed redirected killing assays using Fc
bearing murine target cells. Cells loaded with NKG2D antibodies,
but not isotype control antibodies, triggered cytotoxicity. To fur-
ther demonstrate NKG2D dependent, TCR independent target
recognition, we used FACS puriﬁed activated and expanded CD8
T cells and MHC class I def. targets which can not present peptide
antigen to CD8 T cells. Activated and expanded CD8 T cells
lysed these targets and blocking NKG2D nearly completely inhib-
ited cytolysis. Activated and expanded T cells acquire cytolytic
activity at day 10 of culture, in response to high (300 U/ml), but
not low (30 U/ml) concentrations of IL-2. DAP10 is the only
known adapter protein to transmit NKG2D signals in humans. We
therefore assayed for DAP10 at various time points in culture.
DAP10 was not detected until day 10, and only in response to high
doses of IL-2. Collectively, these studies show that activated and
expanded CD8 T cells recognize targets through a NKG2D
dependent, TCR independent pathway, likely controlled at the
level of DAP10 expression in response to IL-2.
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MODULATION OF TREG CELLS BY EXTRACORPOREAL PHOTOPHERESIS
IN CHRONIC GRAFT-VS-HOST DISEASE
Xie, M., Chan, G., Foss, F. Tufts New England Medical Center, Boston,
MA
While the pathogenesis of chronic graft-vs-host disease has not
been fully elucidated, alloreactive T cells, antigen presenting cells
(APC) and inﬂammatory cytokine secretion have been implicated.
Extracorporeal photopheresis (ECP) has demonstrated efﬁcacy in
patients with steroid-refractory acute and chronic GVHD. While
the mechanism of action of ECP in GVHD remains to be fully
deﬁned, we have demonstrated that clinical response in patients
with extensive, refractory cGVHD was associated with normaliza-
tion of skewed CD4/CD8 ratios and alterations in dendritic cell
and T-cell phenotypes, favoring a DC2/Th2 cytokine proﬁle.
These results suggest that ECP may indirectly or directly modulate
the function or activation of alloreactive T cells in GVHD. In an
attempt to determine the effects of ECP on T cell activation we
have examined the expression of negative co-stimulatory molecules
on T cells from cGVHD patients treated with ECP. We found
signiﬁcant changes in ICOS (inducible costimulatory molecule),
but not PD-l (programmed death gene 1) and CD137 (4-1BB) on
T cells during ECP treatment. Of 16 patients studied, we found
that clinical response to ECP was associated with an increase of
CD4ICOS cells. ICOS T-cells are a strong stimulator of
IL-10 production and Th2 differentiation, and we have previously
reported that ECP treatment is associated with an increase in
IL-10 production by T-helper cells in patients with cGVHD.
Populations of CD4CD25 cells have recently been identiﬁed as
immunoregulatory T cells (Treg), however a recent study of allo-
geneic stem cell grafts suggests that CD4/CD25 coexpression may
Table. Antibody Response to H-Y Antigens
H-Y
antigen: DBY UTY ZFY RPS4Y EIF1AY
>1
H-Y
>1
H-X
F3M
HSCT
34/79
(43%)
18/79
(23%)
17/79
(22%)
5/79
(6%)
5/79
(6%)
40/79
(51%)
14/79
(18%)
M3M
HSCT 0 0
4/46
(9%) 0 0
4/46
(9%)
6/46
(13%)
Normal
Females
11/70
(16%)
4/70
(6%)
3/70
(4%)
15/70
(21%)
9/70
(13%)
29/70
(41%)
12/70
(17%)
Normal
Males
1/64
(2%) 0 0
1/64
(2%)
3/64
(5%)%
5/64
(8%)
5/64
(8%)
Oral Presentations
19BB&MT
be insufﬁcient to identify Treg in humans. To determine whether
the ICOS T-cell populations which were modulated with ECP
treatment were functionally Treg, we isolated CD4CD25
ICOS and CD4CD25 ICOS- cells from patients with
cGVHD before and after ECP therapy and demonstrated that the
CD4CD25ICOS cells functioned as suppressors in an MLR
reaction, suggesting that these cells represent Treg cells. We
conclude that these ICOSCD25CD4 T-helper cells may rep-
resent, in part, immunoregulatory T-cells implicated in the induc-
tion of tolerance. We propose that the mechanism of action of
ECP in cGVHD involves both modulation of DC to induce mat-
uration markers, including possibly the ligand for ICOS (B7H2), as
well as the induction of ICOS expressing CD25 immunoregula-
tory T-helper cells.
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DEFECTIVE POPULATIONS OF REGULATORY T CELLS CORRELATE
WITH THE OCCURRENCE OF CHRONIC GRAFT VERSUS HOST DISEASE
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Zorn, E., Floyd, B., Lee, S.J., Soiffer, R.J., Antin, J.H., Ritz, J.
Dana-Farber Cancer Institute, Boston, MA
Chronic-Graft-Versus-Host-Disease (cGVHD) is a major com-
plication of hematopoietic stem cell transplantation (HSCT). Al-
though the precise etiology of cGVHD is still unknown, recent
evidence suggests that defects in regulation of donor immunity
play an important role in this disease. CD4CD25 regulatory T
cells (T-regs) are critical elements of immune regulation in normal
individuals. T-regs develop in the thymus and reach the periphery
where they inhibit autoreactive effector T cells. After HSCT the
number of recipient hematopoietic cells, including T-regs, are
severely reduced. In adults, residual thymic function is also affected
after transplantation, limiting the reconstitution of CD4CD25
T cells in the periphery. We hypothesized that the occurrence of
cGVHD correlates with a quantitative and qualitative defect in
T-regs reﬂecting a global deregulation of the immune system.
PBMC collected from 29 patients with mild, moderate or severe
cGVHD (group-A), 7 patients who had cGVHD but had resolved
their disease (group-B), and 15 healthy controls (group-C) were
analyzed by complementary methods to assess circulating popula-
tions of T-regs. 1) Percentages of circulating CD4CD25 cells
in total PBL were compared for the 3 groups. 2) Expression of the
T-reg speciﬁc transcription factor foxP3 was assessed by quantita-
tive PCR and reported as a function of CD3 cells. 3) Functional
activity of CD25 T-regs was measured using an in vitro assay
based on the modulation of viral antigen reactive CD8 T cells.
Phenotypic and molecular results were consistent and showed a
signiﬁcant decrease in circulating CD4CD25 cells as well as
lower expression of foxP3 in group A compared to control group
C. Patients with resolved cGVHD (group B) were indistinguish-
able from healthy donors either phenotypically or using the mo-
lecular assay, suggesting that they had recovered normal levels of
T-regs. In functional assays, using samples from cGVHD patients
(group A), a correlation was found between the quantitative assess-
ment of T-regs and their capacity to inhibit class-I anti-viral
effector T cells. In conclusion, these experiments strongly support
our hypothesis that a defect in CD4CD25 T cell populations
correlates with cGVHD and establishes a framework for the de-
velopment of new therapeutic interventions for this disease.
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DONOR T CELL-DERIVED TNF ALPHA REGULATES PULMONARY CHE-
MOKINE EXPRESSION AND THE DEVELOPMENT OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Hildebrandt, G.C.1, Olkiewicz, K.M.1, Corrion, L.1, Chang, Y.2, Liu,
C.3, Ferrara, J.L.M.1, Cooke, K.R.1 1. Dept. of Pediatrics; BMT
Program, University of Michigan, Ann Arbor, MI; 2. Dept. of Pathol-
ogy, University of Michigan, Ann Arbor, MI; 3. Dept. of Pathology,
University of Florida School of Medicine, Gainesville, FL
TNFa is a primary effector molecule in the pathophysiology of
Idiopathic Pneumonia Syndrome (IPS), a frequently fatal compli-
cation after allogeneic (allo) stem cell transplantation (SCT). How-
ever, the contribution of host versus donor derived TNFa to the
development of IPS remains to be determined. Using a lethally
irradiated B6B6D2F1 mouse SCT model, we found that signif-
icant lung injury was present by week 5 after allo SCT compared
to syn controls. Both pulmonary macrophages and T cells were
completely of donor origin at this time. Furthermore, numbers of
TNFa secreting CD4 and CD8 T cells were signiﬁcantly increased
in the BAL ﬂuid (BALF) after allo SCT (CD8: 154 15 vs 2 0.2,
CD4: 76 7 vs 29 2 (x1000)) and pulmonary macrophages from
allo mice secreted signiﬁcantly more TNFa when restimulated
with LPS in vitro (357  127 vs 136  31 pg/ml). We therefore
hypothesized that donor cell-derived TNFa is important to devel-
opment of IPS and tested this by using B6 wild type (wt) or B6
TNFa-/- mice as allo SCT donors: TNFa-/- SCT resulted in
signiﬁcantly reduced lung injury(1.2  0.3 vs 4.1  0.7) and BALF
TNF levels (4.8  3.7 vs 67.4  27.0 pg/ml) compared to wt
controls. These ﬁndings were conﬁrmed in two other allo SCT
systems wherein donor and host differ either at class I or II MHC
only (B6bm1 or B6bm12). In addition, lung injury did not
differ between groups when B6TNFa-/- mice were used as recip-
ients in the bm1B6 system. To determine the contribution of
donor accessory (bone marrow) cell- versus T cell-derived TNFa,
we completed mixing experiments in the B6F1 system wherein
wt or TNFa-/- bone marrow (BM) was supplemented with either
wt or TNFa-/- T cells and found that TNFa from both cellular
sources contributes to IPS. Interestingly, the absence of TNFa
from donor T cells alone was sufﬁcient to signiﬁcantly reduce
levels of the inﬂammatory chemokines MIG, RANTES, MIP-1a,
MCP-1 in the lung by week 2 after SCT. Decreased chemokine
expression directly correlated with the recruitment of inﬂamma-
tory cells to the lung; the severity of IPS was completely abrogated
after allo SCT with wt BM and TNFa-/- T cells (syn: 1.1  0.4;
allo contrl: 4.4  0.6; TNFa-/- T: 2.2  0.9). In conclusion, our
data demonstrate that donor derived TNFa is critical to the de-
velopment of IPS and reveal thus far an unrecognized role for T
cell derived TNFa in the regulation of pulmonary chemokine
expression and the subsequent recruitment of donor effector cells
to the lung after allo SCT.
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SELECTIVE DEPLETION OF T CELL CLONES RESPONSIBLE FOR GVHD
IN A MURINE MODEL
Kappel, B.J., Eng, J.M., Pinilla-Ibarz, J., van den Brink, M.M.R.M.,
Scheinberg, D.A. Memorial Sloan-Kettering Cancer Center, New York,
NY
Graft-versus-host-disease (GVHD), the single most important
complication post allogeneic bone marrow transplantation (BMT),
arises from donor T cell anti-host activity due to mismatches in
major and/or minor histocompatability complexes (MHC and/or
mHAg). Upon encountering a foreign antigen donor T cells un-
dergo antigen speciﬁc clonal expansion, greatly increasing the
number of donor anti-host T cells in circulation. Current therapies
for GVHD include complete non-speciﬁc T cell depletion of bone
marrow (TCD-BM) prior to BMT or immunosuppression post
BMT. However, the use of peptide speciﬁc MHC tetramers allows
for detection of these antigen speciﬁc alloreactive T cell clones.
We hypothesize that speciﬁc targeting and deletion of these T cells
responsible for anti-host activity could prove to be an effective
immunotherapy for the elimination of GVHD.
We have chosen as a murine model of study C57BL/6 (B6) 3
BALB.B, an H2Kb MHC-matched BMT model with one de-
scribed immunodominant mHAg mismatch. This mismatch occurs
at the H60 locus and foreign CD8 T cell receptors recognize a
peptide octamer known as the LYL8 epitope. We propose to show
that the antigen speciﬁc T cells are present, functional, capable of
causing GVHD and removable from the larger population of T
cells. Using phycoerythrin (PE) labeled LYL8 tetramers we iden-
tiﬁed the expanding population of speciﬁc B6 anti-BALB.B T cells
within the spleens of B6 mice immunized with irradiated BALB.B
splenocytes. We then characterized the proliferative and functional
ability of these T cells with mixed lymphocyte reactions and 
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